Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

François Goldwasser

Showing results (1-10 of 185) with videos related to

Pageof 19
Sort By:
Presse Medicale (Paris, France : 1983)|November 29, 2011
[Treatment of metastatic colorectal cancer: an illustration of the changes in the cancer paradigms]François Goldwasser
Therapie|November 24, 2004
[Phase I clinical trials in oncology: ethical issues]François Goldwasser
Anti-Cancer Drugs|August 21, 2002
Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxineJean-Philippe Durand, François Goldwasser
Current Opinion in Clinical Nutrition and Metabolic Care|January 26, 2018
Resting energy metabolism and anticancer treatmentsAnne Jouinot, Clara Vazeille, François Goldwasser
Anti-Cancer Drugs|July 11, 2003
Protection against oxaliplatin acute neurosensory toxicity by venlafaxineJean-Philippe Durand, Catherine Brezault, François Goldwasser
Presse Medicale (Paris, France : 1983)|July 29, 2014
[Biotherapies in metastatic colorectal cancers in 2014]Anne Jouinot, Romain Coriat, Olivier Huillard, et al.
Bulletin Du Cancer|April 21, 2012
[Management of metastatic castration-resistant prostate cancer following docetaxel]Philippe Beuzeboc, Stanislas Ropert, François Goldwasser, et al.
Investigational New Drugs|August 3, 2010
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruptionStanislas Ropert, Olivier Vignaux, Olivier Mir, et al.
Anti-Cancer Drugs|April 23, 2005
Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathyJean-Philippe Durand, Jérôme Alexandre, Loic Guillevin, et al.
Cancer|November 6, 2008
Use of platinum derivatives during pregnancyOlivier Mir, Paul Berveiller, Stanislas Ropert, et al.
Pageof 19

Showing results (1-10 of 185) with videos related to

Sort By:
Pageof 19
Presse Medicale (Paris, France : 1983)|November 29, 2011
[Treatment of metastatic colorectal cancer: an illustration of the changes in the cancer paradigms]François Goldwasser
Therapie|November 24, 2004
[Phase I clinical trials in oncology: ethical issues]François Goldwasser
Anti-Cancer Drugs|August 21, 2002
Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxineJean-Philippe Durand, François Goldwasser
Current Opinion in Clinical Nutrition and Metabolic Care|January 26, 2018
Resting energy metabolism and anticancer treatmentsAnne Jouinot, Clara Vazeille, François Goldwasser
Anti-Cancer Drugs|July 11, 2003
Protection against oxaliplatin acute neurosensory toxicity by venlafaxineJean-Philippe Durand, Catherine Brezault, François Goldwasser
Presse Medicale (Paris, France : 1983)|July 29, 2014
[Biotherapies in metastatic colorectal cancers in 2014]Anne Jouinot, Romain Coriat, Olivier Huillard, et al.
Bulletin Du Cancer|April 21, 2012
[Management of metastatic castration-resistant prostate cancer following docetaxel]Philippe Beuzeboc, Stanislas Ropert, François Goldwasser, et al.
Investigational New Drugs|August 3, 2010
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruptionStanislas Ropert, Olivier Vignaux, Olivier Mir, et al.
Anti-Cancer Drugs|April 23, 2005
Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathyJean-Philippe Durand, Jérôme Alexandre, Loic Guillevin, et al.
Cancer|November 6, 2008
Use of platinum derivatives during pregnancyOlivier Mir, Paul Berveiller, Stanislas Ropert, et al.
Pageof 19